GlassScriptPhysician profile
Gregory K Gahl
NPI 1124105879
$1,511.68
in general payments reported to CMS, 2019-2025
22 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $285 · 2021: $724 · 2024: $17.69 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $100 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.10 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $226.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.42 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $106.44 | 2019-2021 | |
| Amgen INC. | $89.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $83.17 | 2019-2021 | |
| Lilly USA, LLC | $79.59 | 2019-2021 | |
| Glaxosmithkline, LLC. | $55.93 | 2020-2024 | Shingrix |
| Allergan, INC. | $54.51 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $51.88 | 2019-2021 | |
| Astellas Pharma US INC | $46.29 | 2019-2021 | |
| Abbvie INC. | $40.12 | 2019-2021 | |
| Abbott Laboratories | $35.88 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $35.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.49 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.69 | 2019-2020 | |
| Adlon Therapeutics L.P. | $28.67 | 2019-2020 | |
| Dexcom, INC. | $27.27 | 2025 | Dexcom G6 Transmitter |
| Rgh Enterprises LLC | $19.26 | 2025 | |
| Pfizer INC. | $15.32 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.91 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.